US Bancorp
ROIV icon

US Bancorp’s Roivant Sciences ROIV Stock Holding History

US Bancorp’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
5,710
-123
-2% -$3.63K ﹤0.01% 2100
2026
Q1 		$162K Buy
5,833
+1,014
+21% +$26K ﹤0.01% 2123
2025
Q4 		$105K Buy
4,819
+561
+13% +$11.1K ﹤0.01% 2341
2025
Q3 		$64.4K Buy
4,258
+325
+8% +$4.02K ﹤0.01% 2552
2025
Q2 		$44.3K Buy
3,933
+2,009
+104% +$21.8K ﹤0.01% 2834
2025
Q1 		$19.4K Sell
1,924
-812
-30% -$8.78K ﹤0.01% 3187
2024
Q4 		$32.4K Sell
2,736
-542
-17% -$6.41K ﹤0.01% 2947
2024
Q3 		$37.8K Buy
3,278
+1,948
+146% +$22.2K ﹤0.01% 2872
2024
Q2 		$14.1K Buy
1,330
+15
+1% +$164 ﹤0.01% 3186
2024
Q1 		$13.9K Sell
1,315
-118
-8% -$1.27K ﹤0.01% 3226
2023
Q4 		$16.1K Sell
1,433
-433
-23% -$4.22K ﹤0.01% 3140
2023
Q3 		$21.8K Buy
+1,866
New +$21.1K ﹤0.01% 2839
2023
Q2 		– Sell
-79
Closed -$583 – 4113
2023
Q1 		$583 Hold
79
– – ﹤0.01% 3934
2022
Q4 		$631 Buy
+79
New +$439 ﹤0.01% 3977

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

US Bancorp's ROIV Position: Q2 2026 in Review

US Bancorp reduced its Roivant Sciences (ROIV) stake by 2.1% in Q2 2026, selling an estimated $3.63K and leaving 5,710 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

US Bancorp first reported a position in ROIV in Q4 2022 and has held it in 14 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • US Bancorp held 5,710 shares of Roivant Sciences worth $202K as of Q2 2026.
  • US Bancorp sold 123 Roivant Sciences shares in Q2 2026, an estimated $3.63K.
  • Roivant Sciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2100 holding.
  • US Bancorp first reported a position in Roivant Sciences in Q4 2022 and has held it in 14 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.